TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed urothelial cancer~  * Transitional cell carcinoma, adenocarcinoma, or squamous carcinoma (bladder, renal pelvis, ureter, or urethra)~* Previously untreated metastatic or locoregionally advanced (i.e., bulky pelvic nodes) disease OR~* Locally recurrent carcinoma after radiotherapy or cystectomy and no longer eligible for further radiotherapy or surgery~* Measurable disease~PATIENT CHARACTERISTICS:~Age:~* 70 and over OR~* Under 60~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,200/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* Aspartate aminotransferase (SGOT) or alanine aminotransferase (SGPT) no greater than 2 times ULN~Renal:~* Creatinine no greater than ULN~Other:~* HIV negative~* No other concurrent life-threatening medical disorder that would preclude study participation~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior adjuvant chemotherapy is allowed provided administered more than 10 years ago~* No prior gemcitabine, taxanes, or platinum-based adjuvant chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* At least 28 days since prior radiotherapy and recovered~Surgery:~* See Disease Characteristics~* At least 28 days since prior surgery and recovered

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- gemcitabine, paclitaxel (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Eligibility criteria~* Premature newborn infants with bilateral progressive APROP despite complete peripheral retinal ablation.~Inclusion Criteria:~* Inborn babies at participating NICUs (must meet inclusion criteria 3 through 7)~* Outborn babies transferred to participating NICU (must meet inclusion criteria 3 through 7)~* Aggressive posterior ROP~* Adequate/appropriate laser ablation~* Failed standard laser treatment (persistent Plus or recurrent Plus at a minimum of 1 week post-laser)~* Post-menstrual age less than 36 weeks~* Post-menstrual age greater than 30 weeks~Exclusion Criteria:~* Fatal systemic anomaly~* An ocular anomaly of one or both eyes affecting the retina or choroid~* An ocular anomaly precluding use of the RetCam (eg: microphthalmia)~* Neonatologist feels inclusion will unduly challenge the infant~* Refusal of initial consent~* Refusal of subsequent evaluation~* Media opacity precluding fundus visualization (eg: cataract)~* Any ocular or periocular infection(s)

- Gender: ALL
- Minimum Age: 30 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Occlusion for the Prevention of Preterm Birth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The physician in charge considered that a cerclage was indicated.~* Gestational age between 12 and 27 completed weeks.~* Previous late mid-trimester miscarriage, or spontaneous preterm labour and delivery before 28 weeks with or without previous cerclages.~* Previous cerclage because of short cervix.~* Confirmed gestational age defined as gestational age estimated by ultrasound at less than or equal to 22+0 weeks, and/or certain last menstrual period.~* Vaginal infection treated before cerclage.~* Ability to read and understand the relevant national language.~* Consent obtained in accordance with specifications of the local research ethics committee.~* 18 years or more of age and legally competent.~Exclusion Criteria:~* Demonstrated cervical infection.~* Obstetrical complications in the current pregnancy.~* Multiple pregnancies.~* History of a significant abruptio placenta in a previous pregnancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Trial (Type: EXPERIMENTAL): Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (\<25mm)
- Prophylactic Trial (Type: EXPERIMENTAL): Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Histopathologically proven, clinically stage II-III (cTNM according to AJCC/UICC classification), primary squamous cell carcinoma of the thoracic esophagus~* Patients' age above 18 years~* General condition with Karnofsky performance status of \>70~* Circulatory and pulmonary capacity at normal range (FEV1 \>60%; FVC \>60%, NYHA I-II, cardiac output \>40%)~* Normal function of the bone marrow (RBC \>3,5 T/l; PLT \>100 G/l)~* Normal renal (creatinine \<1.5 of the upper limit) and liver (AST or ALT \<2,5 of the upper limit or bilirubin \<1,5 of the upper limit) function~Exclusion Criteria:~* Metastatic disease~* Synchronous malignancy~* History of other cancer within 5 years prior to esophageal cancer treatment~* History of allergic reaction to cisplatin of 5-fluorouracil~* Systemic infection~* Pregnancy or female patients in childbearing age without proper contraceptives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S (Type: ACTIVE_COMPARATOR): esophagectomy
- CHTS (Type: EXPERIMENTAL): neoadjuvant chemotherapy followed by esophagectomy
- CHRTS (Type: EXPERIMENTAL): neoadjuvant chemoradiotherapy followed by esophagectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Italian Platelet Technology Assessment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. adults (\> 18 years)~2. a hematooncology diagnosis (includes patients newly diagnosed and previously diagnosed)~3. expected to require 2 or more PLT transfusions in 4 weeks~4. hospital admission (patients admitted to out-patient clinics will not be enrolled)~5. chemotherapy, related and matched unrelated donor (MUD)transplant recipients~6. recurrent auto-transplanted patients, requiring chemotherapy~7. negative pregnancy test in female patients less than 60 years old~Exclusion Criteria:~1. presence of HLA class I abs on admission with PRA \>20%~2. historical documented record of 2 or more 1 hour post-TX PLT corrected count increments \<5,000 per microliter~3. previously included in IPTAS~4. diagnosis of a solid tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pathogen reduced platelets (Type: EXPERIMENTAL): Transfusion
- Standard platelets (Type: ACTIVE_COMPARATOR): Transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adults who meet AABB (formerly known as the American Association of Blood Banks) criteria for whole blood donation~* females incapable of becoming pregnant~* males agreeing to use contraception during trial~Exclusion Criteria:~* pregnancy or nursing~* abnormal medical history (bleeding disorders, anemia, myocardial ischemia, uncontrolled hypertension, heart disease, epilepsy)~* major surgery~* use of drugs affecting coagulation or RBC function~* recent participation in other trials which may confound results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mirasol Illumination Dose #1 (Type: EXPERIMENTAL): Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
- Mirasol Illumination Dose #2 (Type: EXPERIMENTAL): Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
- Mirasol Illumination Dose #3 (Type: EXPERIMENTAL): Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Delirium in Elderly Patients With Trauma of the Hip

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients aged ≥ 55 years with~* a radiographically confirmed hip fracture~Exclusion Criteria:~* multiple injuries (polytrauma patients)~* previous adverse reaction or known allergy to local anaesthetics or opioids or paracetamol~* skin infection in proximity of injection site~* delirious state at presentation in the ED

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous FICB with local anesthetics (Type: EXPERIMENTAL): With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores.
- Traditional care with systemic analgesia (Type: ACTIVE_COMPARATOR): Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18 yrs. or older~* An elevated PSA (\>2.5 ng/ml) and normal digital rectal exam~* Have elected to proceed with a diagnostic 12-core prostate biopsy~Exclusion Criteria:~* Previous prostate biopsy~* History of prostate cancer~* Urinary tract infections or prostatitis within one year of study entry~* antibiotic use within one month prior to PSA level~* pyuria or bacteruria on urinalysis~* allergy to fluoroquinolones

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Observation only for 2 weeks
- Antibiotic (Type: ACTIVE_COMPARATOR): Ciprofloxacin 500 mg twice daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with biopsy proven advanced melanoma are eligible if there is measurable disease.~* Patients must have a life expectancy of at least 12 weeks.~* Prior surgery, immunotherapy, minimal chemotherapy (1 drug for less than 4 months), or radiotherapy for primary tumor is acceptable but must be completed at least 4 weeks from study entry, and patient should have completely recovered from such procedures.~* Patients must have a Zubrod performance status of 0-2.~* Patients must sign an informed consent.~* Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of ≥ 1500 cells/mm3, hemoglobin \> 8 g/dl, platelet count ≥ 100 000/mm3.~* Patients should have a normal hepatic function with a total bilirubin \< 1.5 the upper limit of normal (ULN) and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) \< 2 times the upper limit of normal (ULN),and adequate renal function as defined by a serum creatinine ≤ 1.5 times the ULN.~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and at least for 3 months.~* Patients with brain metastases are eligible if they have been appropriately treated, are asymptomatic~Exclusion Criteria:~* Pregnant women or nursing mothers are not eligible.~* Patients must not receive any other concurrent chemotherapy or radiation during this trial.~* Patients with severe medical problems that would interfere with the therapy are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy Combination (Type: EXPERIMENTAL): Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years of age~2. Undergoing a procedure which results in the need of a FTSG~3. Willing to provide written informed consent~Exclusion Criteria:~1. Age less than 18 years of age~2. Pregnant women~3. (Use of systemic drugs that can impede wound healing, such retinoids or immune-suppressive drugs)~4. Severe coagulation disorders~5. Severe, uncontrolled systemic comorbidities, such as diabetes, arthritis, etc.~6. Hypersensitivity to 0.25% timolol gel~7. Not willing to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 0.25% Timolol gel applied to full-thickness skin graft (Type: EXPERIMENTAL): 1. During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~2. During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~3. After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks
- Standard of Care dressings (Type: ACTIVE_COMPARATOR): 1. FTSG surgery as per SOC~2. After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* T1DM~* Hyperglycemia \>200 mg/dl~* Bicarbonate ≤ 15 mmol/L~* pH \< 7.3~* Ketonemia~* Ketonuria~* Glucosuria~* Admission to PICU (Pediatric Intensive Care Unit)~* Ages 1-21 years~Exclusion Criteria:~* Patients who received glargine within the last 24 hours~* Patients with sepsis

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
- Treatment Group (Type: EXPERIMENTAL): The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Bearer of lung transplantation (single or double lung, with or without associated cardiac transplantation)~* Suffering from cystic fibrosis~* Aged 18 and over~* With at least 6 months of transplantation~* Having a glomerular filtration rate measured by technical radionuclide \> 30 ml / min~* Having given written consent to the study Patients meeting these criteria will enter in the organic in the study (determination of PIIINP urinary)~Exclusion Criteria:~* Lung transplantation for a condition other than cystic fibrosis~* Patient refused follow-up~* Patients with advanced liver disease (conditions that interfere with the assay of PIIINP)~* Minor~* Pregnant women,~* Major Trust, benefiting from a regime of legal protection (guardianship, trusteeship, safeguarding justice.~* Patient unable to grant informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 65 years old~* Hemoglobin concentration ≥ 9.0 g/dL and \< 11.5 g/dL (women) or \< 12.7 g/dL (men)~* Unexplained anemia~* Serum ferritin level ≥ 20 and ≤ 200 ng/mL~* Able to walk without the use of a walker, motorized device or the assistance of another person.~* Able to understand and willing to provide written informed consent in the absence of dementia~* Must be able to understand and speak in English~Exclusion Criteria:~* Red blood cell transfusions within the past 3 months~* Use of erythropoiesis stimulating agents (ESA) in the past 3 months~* Intravenous Iron Infusions within the past 3 months~* Distance on baseline 6MWT (6 minute walk test) above the median for age and sex~* History of unstable angina or myocardial infarction in the past 3 months~* History of stroke or TIA (transient ischemic attack) the past 3 months~* Uncontrolled hypertension (diastolic blood pressure \> 100 mm Hg or systolic blood pressure \> 160 mm Hg on 2 separate occasions)~* Positive fecal occult blood test within the screening period~* Elevated AST (aspartate aminotransferase) or ALT (alanine aminotransferase) ≥ 2x upper limit of normal~* Documented anaphylactic reaction to iron sucrose infusion in the past~* Subjects initiated on oral iron supplementation within the last 6 weeks, or those initiated on oral iron within the last 3 months who have had at least a one gram/dL improvement in Hb since starting oral iron supplementation

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Intervention Group (Type: EXPERIMENTAL): Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
- Wait List Control (Type: EXPERIMENTAL): Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues